5 news items
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
APLS
10 Jun 24
the GALE long-term extension study were presented at the Clinical Trials at the Summit (CTS) Meeting on June 8 in Park City, Utah. "SYFOVRE
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
APLS
24 May 24
disease activity in only 12 weeks, and the effects were sustained over the long term," said Fadi Fakhouri, M.D., Ph.D., presenting author and professor
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
APLD
APLS
CMI
16 May 24
certain of its officers and directors. If you are a current, long-term shareholder of Inspire Medical Systems holding shares before May 3, 2023, you
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
APLS
7 May 24
Long
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
APLS
1 May 24
and its potential to preserve visual function longer." Oral presentations: Long-term efficacy
- Prev
- 1
- Next